文献速递淋巴瘤

CHRONOS-4:库潘尼西联合利妥昔单抗为基础的免疫化疗治疗复发性惰性B细胞淋巴瘤的3期研究

CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma.
PubMed 文献 · Blood Adv · 2024-01-01

CHRONOS-4是一项3期随机双盲安慰剂对照研究,纳入524例复发性惰性非霍奇金淋巴瘤患者,1:1随机接受库潘尼西(60 mg IV)联合利妥昔单抗和苯达莫司汀(R-B)或安慰剂联合R-B。主要终点无进展生存期(PFS)在两组间无显著差异:库潘尼西联合R-B组中位PFS为32.9个月(95%CI 24.4-38.6),安慰剂联合R-B组为33.3个月(95%CI 27.8-42.8),风险比(HR)1.13(95%CI 0.88-1.44;P=0.83)。库潘尼西联合R-B组严重治疗中出现的不良事件(TEAE)、4级和5级TEAE及治疗中断率更高,部分严重TEAE为感染。

要点

  • 库潘尼西联合R-B组中位PFS 32.9个月 vs 安慰剂联合R-B组33.3个月,HR 1.13(95%CI 0.88-1.44;P=0.83),无显著差异。
  • 两组总生存期(数据尚未成熟)、客观缓解率和缓解持续时间在总体人群或各组织学亚型中均无差异。
  • 库潘尼西联合R-B组严重TEAE、4级和5级TEAE及治疗中断率更高,部分严重TEAE为感染。

核心结论

  • 在复发性惰性非霍奇金淋巴瘤患者中,库潘尼西联合R-B与安慰剂联合R-B相比未提供临床获益,且耐受性更差。

研究设计与样本

  • CHRONOS-4是一项3期、随机、双盲、安慰剂对照研究,纳入524例复发性惰性非霍奇金淋巴瘤患者,1:1随机分配至库潘尼西(60 mg IV)联合R-B组或安慰剂联合R-B组。
  • 库潘尼西/安慰剂与R-B联合给药(每个28天周期的第1、8、15天),最多6个周期,自第7周期起作为单药治疗,最长12个月。
  • 主要研究终点为无进展生存期(PFS)。

主要发现

  • 库潘尼西联合R-B组中位暴露时间为8.5个月(范围0.2-12.9),安慰剂联合R-B组为11.4个月(范围0.1-12.6)。
  • 库潘尼西联合R-B组中位PFS为32.9个月(95%CI 24.4-38.6),安慰剂联合R-B组为33.3个月(95%CI 27.8-42.8),HR 1.13(95%CI 0.88-1.44;P=0.83)。
  • 两组总生存期(数据尚未成熟)、客观缓解率和缓解持续时间在总体人群或各组织学亚型中均无差异。
  • 库潘尼西联合R-B组严重TEAE、4级和5级TEAE及治疗中断率更高,部分严重TEAE为感染。

关键数值与推荐

  • 库潘尼西联合R-B组中位PFS 32.9个月(95%CI 24.4-38.6)vs 安慰剂联合R-B组33.3个月(95%CI 27.8-42.8),HR 1.13(95%CI 0.88-1.44;P=0.83)。
  • 库潘尼西联合R-B组中位暴露时间8.5个月(范围0.2-12.9)vs 安慰剂联合R-B组11.4个月(范围0.1-12.6)。

临床怎么用

  • 原文结论为库潘尼西联合R-B与安慰剂联合R-B相比未提供临床获益且耐受性更差,未据此给出推荐。

局限性

  • 总生存期数据尚未成熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Copanlisib, a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the α and δ isoforms, previously demonstrated durable responses as monotherapy and improved progression-free survival (PFS) in combination with rituximab in patients with relapsed indolent non-Hodgkin lymphoma (iNHL). CHRONOS-4 was a phase 3, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of copanlisib in combination with standard immunochemotherapy in patients with relapsed iNHL. Patients (n = 524) were randomized (1:1) to copanlisib (60 mg IV) plus immunochemotherapy (rituximab and bendamustine [R-B] or placebo plus R-B). Copanlisib/placebo were administered with R-B (days 1, 8, and 15 of each 28-day cycle) for ≤6 cycles and as monotherapy from cycle 7 up to 12 months. The primary study end point was PFS. Median exposure was 8.5 months (0.2-12.9) for copanlisib plus R-B and 11.4 months (0.1-12.6) for placebo plus R-B. Median PFS was 32.9 months (95% confidence interval [CI], 24.4-38.6) for copanlisib plus R-B and 33.3 months (95% CI, 27.8-42.8) for placebo plus R-B (hazard ratio, 1.13; 95% CI, 0.88-1.44; P = .83). No differences between treatment arms were observed in overall survival (data not yet mature), objective response rate, and duration of response for the overall population or individual histology types. Overall, copanlisib plus R-B was associated with higher rates of serious treatment-emergent adverse events (TEAEs), grade 4 and 5 TEAEs, and treatment discontinuation. A number of serious TEAEs were infections. Overall, copanlisib plus R-B did not provide clinical benefit vs placebo plus R-B and was associated with worse tolerability in patients with relapsed iNHL. This trial was registered at www.ClinicalTrials.gov as #NCT02626455.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zinzani PL, Wang H, Feng J, et al. CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma. Blood Adv. 2024. PMID: 39058951. doi:10.1182/bloodadvances.2024013236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。